Flagship · Bulletin

Macro rationale

Live inputs keep us out of risk-off: VIX 14.63 (-21% vs 200d), HY OAS 2.71%, 2s10s +0.38 not inverted, S&P at a record 7,799. But the macro digest's stagflation vise is intact — July NFP -23k (first negative of cycle, -103k prior revisions), participation 61.4%, headline CPI 3.4% with energy +14.7% YoY, and an FOMC pinned at 3.50-3.75% with all three dissenters wanting a HIKE. Real 10y yield 2.43% is genuinely restrictive. That is the complacency gap: credit and vol price perfection while labor and real rates price late cycle. NEUTRAL is the honest call, held at the escalated top of the band (extension escalator active: QQQ +12.37% vs 200d) rather than adding beta into a record tape. Nothing in this run's trigger changes a named capital flow. The auto-fire is a price event, not a funder event: AVGO -5.81% on a day with no company news — the $100B+ custom-ASIC pipeline, the VMware renewal base and the $7B+ buyback are unchanged; that is multiple compression in a 71x trailing / 27x forward gap, exactly the risk the briefing already flagged. LUNR +8.32% is the OPPOSITE — a $600M NASA lunar funding headline that CONFIRMS the government-backlog thesis that is the entire reason the position exists. Neither is a reason to trade. stale_policy=YES binds: no opens, no adds. FSLR and RGEN are therefore declined on mechanics as well as on merit — FSLR's earnings are a 45X policy annuity into an OBBBA phase-out the brief explicitly tells us to lean away from (subsidy-push, not demand-pull), and RGEN is a fine franchise at RSI70 / +19% over its 200dma in the pillar the brief keeps underweight on real yields. Cash: carried 29.03% is above the enforced escalated ceiling of 25%. I bring the declared level to 25% for band compliance — that is a mechanical cure of an above-ceiling carry, not a new risk appetite; stale_policy blocks redeploying it into adds this week.

Thesis

Zero tickets. This is a price-triggered event run, and neither trigger touches a funder. AVGO -5.81% is a de-rating day on an intact franchise (custom ASIC ~70% share, VMware infrastructure lock-in, 69.5% gross margin, $7B+ buyback) — the §6.5 test asks what changed in the BUSINESS, and the answer is nothing; score 63 is drift, and drift is not an exit trigger. LUNR +8.32% on the $600M NASA lunar award is confirmation of the named backlog thesis, and it is 3 days inside its lock with unlock=none regardless. Under stale_policy I cannot add to either, so the correct output is the standing book re-affirmed verbatim at prior entry weights, delta 0 on all fifteen names. Entry evaluation, on the record: FSLR (score 67) declined — the red team is right that a large share of EPS is a 45X credit annuity Congress is actively phasing down under OBBBA, CdTe is efficiency-disadvantaged vs TOPCon/HJT, and the brief tells us to own demand-pull scarcity (grid, uranium, oil cash flow) not subsidy-push renewables; I cannot refute the kill case, so I do not open it. RGEN (score 66) declined — quality franchise, hostile entry: RSI70, +19% over its 200dma, ~10x sales on mid-single-digit organic growth, Protein A sold through a customer (Cytiva/Danaher) with both the incentive and capability to insource, into the pillar the brief underweights while the 10y sits at 4.68%. Mid-cap sleeve reviewed: AMKR (contracted TSMC CoWoS overflow, 180-190k wafers/yr) remains the best bench candidate and DRS/RKL

Reflection

Two price events, zero funder events: AVGO -5.81% is de-rating with no news, LUNR +8.32% is a $600M NASA award confirming its thesis. No tickets.

For six straight runs my triggers have been arithmetic or tape, never a broken funder — and the last three burned on trims that never executed. So the discipline I want to keep this week is the opposite of activity: with stale_policy blocking opens and adds, and both trigger names showing intact funders, the only defensible ticket is the cash-band cure (29.03% carried above the 25% escalated ceiling). Nagging tension: AVGO and ASML both sit at score 62-63 on drift, not on any named break, and I keep restating that drift is not an exit trigger — true, but if a third compute name joins them I sh

Positions (15)

• MUMicron Technologycompute

  hold4.08%88
  flow acceleratingconf

  Funder

  Only US-domiciled leading-edge DRAM/HBM franchise: 84.6% gross margin, FCF positive, and genuine supply discipline after two decades of cycle abuse — the three-player HBM oligopoly (SK Hynix/Micron/Samsung) is the tightest structural bottleneck in the AI stack. Named flow: 16 multi-year Strategic Customer Agreements worth ~$100B of contracted supply, 2026 HBM production entirely sold out across al

  Unwind

  Erosion of the 16-SCA contract book; HBM oversupply as new capacity lands late-2026; a hyperscaler capex cut; or CXMT Beijing capacity landing at scale in commodity DRAM and bleeding into HBM pricing.

  Catalyst

  Next quarterly report — HBM4 qualification progress and whether the SCA contract book converts at contracted price rather than spot.

  Scenarios · 12mo targets

  $1,150.00 base

  $1,500.00 bull — HBM4 qualifies at Blackwell/Rubin volumes, sold-out 2026 extends into 2027 and SCA pricing holds — memory earns through the cycle rather than round-tripping.

  $700.00 bear — Late-2026 capacity additions plus CXMT commodity DRAM break pricing discipline; contracted book reprices and the 1,368% earnings growth normalizes hard.

• TSMTaiwan Semiconductor Manufacturingcompute

  hold6.16%86
  flow steadyconf

  Funder

  World-leading foundry with an effective monopoly at <=3nm — every meaningful AI accelerator routes through it. >50% gross margin, prodigious FCF, famously disciplined capex, ~73% foundry share and ~90% of advanced AI chip production. Named flow: CHIPS $6.6B Arizona disbursement locked, CoWoS capacity booked out through 2026 (scaling 75k to 130k wafers/month) with 180-190k wafers/yr overflowing to

  Unwind

  Gross margin sustained <50% for two consecutive quarters; a rival closing the leading-edge yield gap; a Taiwan-strait event Arizona capacity cannot offset; or a hyperscaler capex cut breaking the advanced-node order book.

  Catalyst

  Monthly revenue prints and the next quarterly capex guide — the tell on whether 2027 leading-edge bookings are still accelerating.

  Scenarios · 12mo targets

  $500.00 base

  $620.00 bull — 2nm ramps on schedule with the announced price increases sticking; CoWoS expansion converts backlog and foundry share moves higher still.

  $340.00 bear — A hyperscaler digestion quarter plus Taiwan-risk premium re-rating compresses the multiple even with earnings intact.

• NVDANVIDIAcompute

  hold3.81%74
  flow steadyconf

  Funder

  AI-accelerator franchise with the CUDA software moat — ~74.9% gross margin, fortress balance sheet, developer lock-in no ASIC rival has replicated in a decade. Named flow: ~$725B 2026 hyperscaler capex anchored on Blackwell/Rubin (MSFT $190B, AMZN $200B, GOOGL $180-190B, META $125-145B), the Stargate $500B JV, the $500B Goldman/BlackRock/KKR AI-infrastructure financing initiative, and CoreWeave's

  Unwind

  Data-center revenue YoY <20% for two consecutive quarters; hyperscaler in-sourcing plus AMD wins pushing competitor share toward the 25% TAM invalidation line; or a compute export-control tightening that removes a material share of demand.

  Catalyst

  Next quarterly print — data-center growth rate and any change in hyperscaler capex commentary.

  Scenarios · 12mo targets

  $265.00 base

  $330.00 bull — Rubin ramps into an un-dented capex line and inference share holds ~74%; the debt-funded financing wave extends the cycle rather than ending it.

  $165.00 bear — Custom ASIC in-sourcing plus a first genuine capex-digestion quarter takes data-center growth below 20% and the multiple with it.

• ASMLASML Holdingcompute

  hold3.13%62
  flow softeningconf

  Funder

  EUV / High-NA monopoly — the single most irreplaceable tool in advanced semis, no commercial-scale alternative at 2nm, multi-year backlog and ~50% gross margin with an installed-base service annuity that keeps compounding after the tool ships. Named flow: Norway GPFG holds, Coatue/Third Point added Q1; the TSMC/Samsung/Intel 2025-27 EUV orderbook backstops cash flow, and Intel's July 2026 Ultra 3

  Unwind

  Book-to-bill <0.7 for three consecutive quarters; a Dutch/US export-control tightening removing a material share of the orderbook; a credible non-EUV patterning path at 2nm; or China DUV self-sufficiency spreading from DUV into the EUV-served node.

  Catalyst

  Next quarterly bookings print — the China revenue mix (41% to 16%) and whether High-NA orders offset the DUV decline.

  Scenarios · 12mo targets

  $2,100.00 base

  $2,600.00 bull — High-NA orders convert on the 2nm ramp and the service annuity offsets China DUV erosion; bookings re-accelerate above 1.0 book-to-bill.

  $1,400.00 bear — Chinese DUV self-sufficiency keeps compounding while a foundry capex pause delays High-NA — bookings stall and the monopoly premium compresses.

• AVGOBroadcomcompute

  hold3.09%63
  flow steadyconf

  Funder

  Custom-silicon ASIC leader (~70% share) plus the VMware infrastructure-software moat — 69.5% gross margin, huge FCF, $7B+ annual buyback, serial dividend grower, and one of the best capital-allocation records in semis under Tan. Named flow: Google TPU multi-generation, Meta MTIA, and the Anthropic 3.5GW ASIC commitment; AI segment previously confirmed +143% to $10.8B with $30B+ bookings, and the c

  Unwind

  AI custom-chip revenue stalling below a ~$25B annual run-rate; full hyperscaler in-sourcing displacing the ASIC design franchise; VMware renewal churn breaking the software annuity; or FCF failing to cover the buyback+dividend.

  Catalyst

  Next quarterly report — AI segment run-rate and VMware renewal retention; the single-day drawdown resolves there, not on the tape.

  Scenarios · 12mo targets

  $470.00 base

  $580.00 bull — Custom-ASIC revenue compounds toward the $100B ambition as Google/Meta/Anthropic programs ramp; the 71x trailing multiple closes to the 27x forward via earnings.

  $300.00 bear — A hyperscaler pulls an ASIC program in-house or delays a generation while VMware churn bites — the trailing-to-forward valuation gap closes downward instead.

• ANETArista Networkscompute

  hold2.75%65
  flow steadyconf

  Funder

  Durable hyperscaler-networking franchise and a consistent share-gainer since 2004 — 62.9% gross margin, net cash, no debt, and the single-image EOS software moat that keeps switching costs high; Ullal-led capital discipline. Named flow: Microsoft and Meta as named anchor customers funding growth, the first $3B quarter (Q2 revenue +37.7% YoY) with full-year guidance raised to $12.6B / 40% growth, a

  Unwind

  Microsoft+Meta combined concentration >50% with revenue decelerating; Spectrum-X or whitebox displacing EOS in a NAMED hyperscaler footprint; gross margin breaking below the high-50s; or forward P/E sustained above the ~45x invalidation line on decelerating bookings.

  Catalyst

  Any disclosed hyperscaler win for NVIDIA Spectrum-X inside an existing Arista footprint — that is the hard trigger, not the revenue headline.

  Scenarios · 12mo targets

  $230.00 base

  $290.00 bull — 1.6T AI fabric wins back-end cluster share and the customer base broadens beyond the two anchors; 40% growth guidance proves conservative.

  $145.00 bear — Spectrum-X (already $14.8B, +199% YoY) displaces EOS at Microsoft or Meta; concentration risk becomes realized revenue loss at a ~48x forward multiple.

• GEVGE Vernovaenergy

  hold6.69%61
  flow steadyconf

  Funder

  Gas-turbine and grid franchise with genuine pricing power — record ~$176B backlog, heavy-duty turbines sold out through 2030, 10-20% price realization on new orders, quadrupled FCF, and a three-player global oligopoly (GE Vernova/Siemens Energy/Mitsubishi) that cannot be entered quickly. Named flow: Norway GPFG added post-spin; Oracle/Alphabet datacenter capex pulling turbine and grid orders throu

  Unwind

  Gas-turbine backlog cancellation or a hyperscaler power-capex cut; wind-segment losses widening enough to consume gas-segment profit; or EV/EBITDA breaching the ~25x exit ceiling on decelerating orders.

  Catalyst

  Next quarterly orders/backlog print and the DOE SPARK award announcements — confirmation the T&D bottleneck keeps funding equipment orders.

  Scenarios · 12mo targets

  $1,250.00 base

  $1,550.00 bull — Backlog keeps converting at 10-20% price realization while wind losses narrow; the grid bottleneck keeps power equipment scarce into 2030.

  $780.00 bear — A datacenter power-capex pause plus widening wind losses hits a stock already up 674% since spin at 34x 2026 earnings — multiple compression on a stretched name.

• SCCOSouthern Copperenergy

  hold8.30%67
  flow steadyconf

  Funder

  Tail-risk hedge slot (§5.3): lowest-cost major copper producer with the industry's largest reserve base, 67.6% gross margin, FCF positive and a large dividend; Grupo Mexico control enforces capital discipline through the cycle. Named flow: ~320k tonne 2026 copper supply deficit with prices at record highs above $6.50/lb, record quarterly net income, BHP's own results showing copper now out-earning

  Unwind

  Copper price collapse breaking the deficit thesis; Tia Maria / Los Chancas permitting reversal; a dividend cut signalling balance-sheet stress; or a Peruvian/Mexican fiscal or nationalization shock.

  Catalyst

  Tia Maria / Los Chancas permitting milestones and the next quarterly copper realization — the entry trigger is only partly confirmed until permitting unblocks.

  Scenarios · 12mo targets

  $210.00 base

  $255.00 bull — The structural deficit widens as grid and datacenter demand compounds while no major new supply lands; Tia Maria permits unblock growth volume.

  $145.00 bear — China property drag plus a global growth scare breaks the copper price; Peruvian permitting or fiscal politics re-price the asset base.

• NEMNewmont Corporationenergy

  hold7.44%84
  flow steadyconf

  Funder

  Tail-risk equity hedge (§5.3): largest gold producer with tier-1 long-life assets, strong post-Newcrest FCF and dividend, and visibly improving cost discipline after the divestiture program. Named flow: sustained central-bank gold accumulation as reserve managers diversify out of USD, a stagflation setup the miner is levered to (headline CPI 3.4%, Fed pinned with hike dissents, real yield 2.43%),

  Unwind

  Cost overruns or mine disappointments breaking FCF and the dividend; durable disinflation plus a real-rate surge removing the stagflation-hedge rationale; or a persistent miner-vs-physical de-rating (GDX chronically lagging SLV/GLD) showing the equity is no longer the right expression.

  Catalyst

  Next quarterly AISC print and central-bank gold purchase data — cost discipline is the variable, not the gold price.

  Scenarios · 12mo targets

  $135.00 base

  $165.00 bull — Stagflation persists, the Fed cannot ease into 3.4% headline, and central banks keep buying — miner margins expand faster than the metal.

  $92.00 bear — Core CPI breaks below 2.2%, real yields surge and the hedge rationale evaporates while RSI 71 unwinds; cost inflation eats the FCF.

• KTOSKratos Defensedefense

  hold8.92%64
  flow steadyconf

  Funder

  Tactical drones (XQ-58A Valkyrie), hypersonics and turbine engines — a scarce non-prime supplier of attritable airframes with a decade of embedded program positions that primes cannot easily displace. Named flow: DoD MACH-TB 2.0 $1.45B IDIQ ceiling, Project Helios $68.3M single-award hypersonic materials, USMC Valkyrie MUX mods, a $49M NSWC Oriole solid-rocket-motor award into the SRM bottleneck,

  Unwind

  Backlog or contract cancellations; margin failing to inflect through the drone ramp with FCF staying negative; a DoD unmanned-systems funding cut; or an FY2027 appropriations outcome that strands the drone-dominance line.

  Catalyst

  FY2027 appropriations / CR resolution (Dec 4 deadline) and the next hypersonics facility contract award; next earnings must show margin inflection.

  Scenarios · 12mo targets

  $78.00 base

  $95.00 bull — Drone-dominance procurement converts to production orders and the hypersonics facility ramps — revenue crosses tier-one scale with margins finally inflecting.

  $45.00 bear — A CR through the midterms freezes new starts, FCF stays negative through the ramp, and a stock at RSI 71 but -12% below its 200dma re-rates down.

• HEIHEICOdefense

  hold10.23%68
  flow steadyconf

  Funder

  Defense/aero aftermarket compounder and a textbook 20-30 year franchise — the Mendelson family has owned and run it since 1957, compounding FCF at 20%+ with a disciplined serial-acquisition model (~$1B/yr) and roughly 50% of the FAA-approved PMA parts market. Named flow: Q2 record net income +49% YoY with FSG $929M vs $864M consensus and ETG op income +56%, NDAA mandatory funding plus the commerci

  Unwind

  Organic growth decelerating below 6% WITH margin compression; a value-destroying large acquisition breaking the serial-acquirer discipline; forward P/E sustained above ~54x on decelerating growth; or a Mendelson management succession break.

  Catalyst

  Next quarterly report — FSG/ETG organic growth vs the 6% floor, and acquisition pace and pricing.

  Scenarios · 12mo targets

  $420.00 base

  $500.00 bull — Aftermarket demand stays tight, ETG margin expansion continues and the acquisition machine keeps buying at disciplined multiples — compounding as it has for 40 years.

  $275.00 bear — Any organic deceleration at a ~54x forward multiple de-rates hard; a large deal at a bad price would break the allocation record that is the thesis.

• LLYEli Lillybiology

  hold3.02%73
  flow acceleratingconf

  Funder

  Premier pharma compounder — the Mounjaro/Zepbound tirzepatide franchise (~60% US share; Q2 Mounjaro $9.9B, Zepbound $4.9B) plus oral orforglipron and retatrutide in Phase 3, on 85.8% gross margin with heavy FCF and a $27B manufacturing expansion that is itself a moat against supply-constrained rivals. Named flow: Foundayo won Europe's first oral weight-loss approval with a no-food-restriction adva

  Unwind

  Tirzepatide US script share falling >5pts to Novo over two quarters; retatrutide Phase 3 disappointing on safety or durability; or IRA/MFP negotiation reaching the GLP-1 franchise and repricing it structurally.

  Catalyst

  Retatrutide Phase 3 readouts and the Q1 2027 filing window; near-term, the next quarterly script-share print vs Novo.

  Scenarios · 12mo targets

  $1,400.00 base

  $1,700.00 bull — Oral orforglipron opens the primary-care channel Europe just validated and retatrutide extends the franchise a decade — obesity TAM compounds with LLY holding share.

  $950.00 bear — IRA/MFP negotiation reaches GLP-1 pricing or retatrutide disappoints on safety, and a franchise priced for a decade of growth de-rates.

• VRTXVertex Pharmaceuticalsbiology

  hold2.51%82
  flow steadyconf

  Funder

  Durable biology compounder: the cystic-fibrosis monopoly (Trikafta/Alyftrek) is a self-funding cash engine with 85.3% gross margin, no meaningful competition and a fortress net-cash balance sheet — insulated from the rate vise that hits pre-revenue biotech. Named flow: the $10B Crinetics acquisition funded from balance sheet extends the franchise into endocrinology, Casgevy commercializing across

  Unwind

  The CF franchise eroding faster than non-CF revenue can replace it; the Crinetics integration destroying value or pushing forward P/E toward the 30x invalidation line; or a suzetrigine launch that fails to convert prescriber behavior.

  Catalyst

  Next earnings — suzetrigine launch metrics and the first Crinetics integration detail.

  Scenarios · 12mo targets

  $590.00 base

  $700.00 bull — Suzetrigine converts a real share of the non-opioid pain market and Crinetics adds a second growth leg — CF cash funds diversification without dilution.

  $420.00 bear — $10B spent on Crinetics dilutes returns while CF plateaus and suzetrigine uptake stays slow; the franchise premium compresses.

• ARGXargenxbiology

  hold2.46%70
  flow steadyconf

  Funder

  argenx — the Vyvgart/Vyvgart Hytrulo (efgartigimod) FcRn autoimmune franchise: first-mover platform with a decade of indication runway, self-funded, commercial-stage, high-margin and net cash. Named flow: FDA expanded gMG approval to all serotypes including seronegative (~18% TAM expansion), Sanofi's CIDP trial FAILURE clearing the nearest competitive threat, myositis/Sjogren's data from the June

  Unwind

  Vyvgart revenue growth stalling; a pipeline indication failure in myositis or Sjogren's; a competitor FcRn entrant taking measurable share; or the Forte deal turning into a value-destroying integration.

  Catalyst

  Forte tender outcome and the next myositis/Sjogren's readout; quarterly Vyvgart revenue is the running check.

  Scenarios · 12mo targets

  $1,000.00 base

  $1,200.00 bull — Sjogren's and myositis labels land and Hytrulo subcutaneous conversion accelerates — the FcRn franchise compounds indication by indication with no credible rival.

  $680.00 bear — A pipeline indication misses or an FcRn competitor lands; Vyvgart growth decelerates and a pre-peak-sales multiple resets.

• LUNRcompute

  hold1.33%54
  flow acceleratingconf

  Funder

  Intuitive Machines — named government backlog is the whole thesis: NASA Near Space Network IDIQ ($4.82B ceiling, active), a fresh $148.3M firm-fixed-price CLPS task order, the ~$600M NASA lunar award tranche that drove today's +8.32%, the US Space Force Andromeda IDIQ ($6.2B ceiling) and a record ~$1.1B contracted backlog supporting $1B FY2026 revenue guidance and a stated 2027 profitability path.

  Unwind

  Backlog conversion stalling; the 2027 profitability pathway breaking; a NASA CLPS or SDA program funding cut (a CR that strands new starts is the near-term risk); or further insider selling on top of the CTO's $3.3M disposal.

  Catalyst

  Next quarterly backlog-to-revenue conversion print and the FY2027 NASA appropriations/CR outcome.

  Scenarios · 12mo targets

  $24.00 base

  $34.00 bull — Backlog converts on schedule, FY2026 revenue lands near $1B guidance and the 2027 profitability path is confirmed — the government annuity gets a real multiple.

  $10.00 bear — A CR or CLPS funding cut strands task orders, conversion slips and a cash-burning small cap has to raise equity at a discount.

Warnings

• §2 cap re-applied after pillar tilt: HEI
• §5.4 dry-powder: cash_pct 25% above base band top 15% allowed by §3b unfilled-sleeve headroom (+17.5pp, eff top 32.5%)
• cash_band: final cash 26.08% above neutral base band top 15% (escalator active: extension; §3b dry-powder headroom +17.5pp (unfilled opportunistic sleeve → cash)) (§5.4)
• position_count: 15 < 16 after mechanical closes (§2 floor) — book under-populated; strategist must open replacements next run
• hedge_floor: only 2/3 tail-risk names held (floor escalated: AI-load 31% > 30%) — open a gold/oil/diversified-commodity hedge (§5.3); uranium & power-gen do not count
• live_sizing: 1 ticket(s) re-expressed against the executed ledger (§6.6)

Conviction-lock actions

1. Turn 1ConvictionGuard (§6.5d)

   —

Cost breakdown

Per-call cost computed from cost.js pricing constants (Opus 4.7, Sonnet 4.6, Haiku 4.5). Cache-read tokens billed at 10% of input. See Cost & ROI for the rolling 30-day ledger.